0001396814-24-000037.txt : 20240308 0001396814-24-000037.hdr.sgml : 20240308 20240308173351 ACCESSION NUMBER: 0001396814-24-000037 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240306 FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PACE GARY W CENTRAL INDEX KEY: 0001184778 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 24735764 MAIL ADDRESS: STREET 1: C/O RESMED INC STREET 2: 14040 DANIELSON STREET CITY: POWAY STATE: CA ZIP: 92064-6857 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 BUSINESS PHONE: 813-553-6680 MAIL ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 wk-form4_1709937219.xml FORM 4 X0508 4 2024-03-06 0 0001396814 Pacira BioSciences, Inc. PCRX 0001184778 PACE GARY W C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890 TAMPA FL 33609 1 0 0 0 0 Common Stock 2024-03-06 4 S 0 1066 29.67 D 140384 D Common Stock 2024-03-07 4 S 0 28257 30.81 D 112127 D Common Stock 2024-03-08 4 S 0 90000 30.60 D 22127 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.550 to $30.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.300 to $30.860, inclusive. /s/ Kristen Williams, Attorney-in-Fact 2024-03-08